GlycoNex to Showcase Innovations at Asia-Taiwan 2025 Event
Highlighting advancements in glycan-directed cancer immunotherapies and biosimilars
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company dedicated to developing glycan-directed cancer immunotherapies, has announced its participation in the upcoming BIO Asia-Taiwan International Conference & Exhibition. The event is scheduled to take place from July 23-27 at the Nangang Exhibition Center.
Engaging with Stakeholders
At BIO Asia-Taiwan 2025, GlycoNex's leadership team will engage with investors, potential collaborators, and members of the biotechnology community. This important gathering will serve as a platform for discussing the company’s strategic directions, clinical advancements, and innovations in glycan-based therapies and biosimilars.
Focus on Key Development Programs
During this event, GlycoNex will showcase progress regarding their impactful development programs. One highlight is GNX1021, a groundbreaking antibody-drug conjugate (ADC) that aims to revolutionize treatment approaches. Additionally, they will provide insights into SPD8, a denosumab biosimilar that is currently undergoing Phase 3 clinical trials, and GlycoSH, an innovative anti-glycan antibody bank that opens up new avenues for early drug discovery.
About the Event
The BIO Asia-Taiwan International Conference & Exhibition is an anticipated gathering of top biotechnology firms and innovators. This year’s event promises to deliver insightful discussions and networking opportunities. Details of the event are as follows:
Key Information:
Event: 2025 BIO Asia-Taiwan International Conference & Exhibition
Date and Time: July 23-27, 2025
Location: Nangang Exhibition Center, Taipei
Website: https://bioasiataiwan.com/
About GlycoNex, Inc.
GlycoNex, Inc. is a clinical-stage biotechnology company focused on pioneering glycan-directed cancer immunotherapies that aim to inhibit tumor progression while reducing adverse side effects. The company is fortified by a dynamic pipeline, led by GNX102, a humanized monoclonal antibody designed to directly target abnormal sugar molecules present in cancer cells. The initial Phase 1 clinical trials have shown promising safety and efficacy results.
Advancing Antibody-Drug Conjugates
GlycoNex is also committed to developing a range of ADCs that specifically target cancer cells while leaving healthy tissues unharmed. Among these is GNX1021, a novel ADC crafted to tackle branched Lewis B/Y (bLeB/Y), known for its significant therapeutic potential. GlycoNex is headquartered in New Taipei City, dedicated to advancing the frontiers of cancer treatment.
Contact Information
Investor Relations:
Tiberend Strategic Advisors, Inc.
David Irish
Media Relations:
Eric Reiss
Frequently Asked Questions
What innovations will GlycoNex present at the event?
GlycoNex will present advancements in glycan-directed cancer therapies and highlight key products like GNX1021 and SPD8.
Where is the BIO Asia-Taiwan event taking place?
The event will be held at the Nangang Exhibition Center in Taipei.
What is the main focus of GlycoNex?
The main focus of GlycoNex is the development of glycan-directed cancer immunotherapies and biosimilars.
What are antibody-drug conjugates?
ADCs are targeted cancer therapies designed to deliver cytotoxic agents directly to cancer cells, maximizing treatment efficacy while minimizing damage to healthy tissue.
When is the BIO Asia-Taiwan event scheduled?
The event is scheduled from July 23-27, 2025.
